Webster Bank N. A. Trims Stake in Hologic, Inc. (NASDAQ:HOLX)

Webster Bank N. A. reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,324 shares of the medical equipment provider’s stock after selling 659 shares during the period. Webster Bank N. A.’s holdings in Hologic were worth $1,648,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HOLX. CHURCHILL MANAGEMENT Corp increased its position in shares of Hologic by 15.9% in the second quarter. CHURCHILL MANAGEMENT Corp now owns 89,616 shares of the medical equipment provider’s stock valued at $4,303,000 after acquiring an additional 12,273 shares during the period. First Trust Advisors LP grew its holdings in Hologic by 199.8% in the first quarter. First Trust Advisors LP now owns 260,794 shares of the medical equipment provider’s stock worth $12,622,000 after purchasing an additional 173,810 shares during the period. FMR LLC grew its holdings in Hologic by 419.2% in the first quarter. FMR LLC now owns 13,264,384 shares of the medical equipment provider’s stock worth $641,996,000 after purchasing an additional 10,709,693 shares during the period. Cleararc Capital Inc. purchased a new stake in Hologic in the first quarter worth about $217,000. Finally, Cerebellum GP LLC grew its holdings in Hologic by 414.3% in the first quarter. Cerebellum GP LLC now owns 5,328 shares of the medical equipment provider’s stock worth $258,000 after purchasing an additional 4,292 shares during the period. Hedge funds and other institutional investors own 96.45% of the company’s stock.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Wednesday, May 29th. Canaccord Genuity restated a “hold” rating and issued a $52.00 price objective on shares of Hologic in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Hologic in a report on Thursday. ValuEngine cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Thursday. Finally, BTIG Research restated a “buy” rating and issued a $52.00 price objective on shares of Hologic in a report on Thursday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. Hologic currently has an average rating of “Hold” and a consensus target price of $46.77.

In related news, insider Peter J. Valenti III sold 4,545 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $44.07, for a total transaction of $200,298.15. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.90% of the stock is owned by corporate insiders.

Hologic stock traded down $0.76 during midday trading on Friday, reaching $50.07. 11,603 shares of the company traded hands, compared to its average volume of 1,700,057. The stock has a market cap of $13.80 billion, a price-to-earnings ratio of 22.55, a price-to-earnings-growth ratio of 2.38 and a beta of 0.72. The company’s 50 day simple moving average is $48.43. Hologic, Inc. has a 12 month low of $37.47 and a 12 month high of $52.19. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.45 and a quick ratio of 1.02.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.02. The company had revenue of $852.40 million for the quarter, compared to the consensus estimate of $836.91 million. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.58 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 2.42 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Cash Flow

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.